Methods of Treating Cancer with PK1 or Aurora Kinase Inhibitors by Using Parkin as a Biomarker

Technology #2015-312

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Zhenkun Lou Ph.D.
SeungBaek Lee Ph.D.
JungJin Kim Ph.D.
Managed By
Tim D. Argo
Patent Protection
US Patent Pending
US Patent Pending

Mayo Clinic has discovered that the Parkin protein is a mitotic regulator. Cancer cells with deficiency or mutations in Parkin have an increase in mitotic regulator expression leading to tumorigenesis and an increase in sensitivity of Pk1 and Aurora kinase inhibitors. This newly identified mechanism has revealed that Parkin mutations may be used as a biomarker for measuring the sensitivity of PK1 and Aurora kinase inhibitors.